A Clinical Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Injection (CNCT19) in the Treatment of Cluster of Differentiation 19 (CD19) Positive Relapsed or Refractory B Cell Malignancies

NCT04011293 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Relapsed or Refractory Hematological Malignancies

Interventions

BIOLOGICAL: CNCT19

Sponsor

Shandong University

Collaborators

[object Object]